Nykode Therapeutics ASA announced a collaboration with the GOG Foundation Inc. to conduct a clinical trial of VB10.16 in combination with an immune checkpoint inhibitor for the treatment of advanced cervical cancer in the U.S. The VB-C-04 trial will evaluate the combination therapies in patients with cervical cancer that have progressed following first line treatment. Nykode has previously reported positive interim data from the Phase 2 VB-C-02 trial in Europe in patients with heavily pre-treated advanced cervical cancer. VB10.16, wholly owned by Nykode, is a potentially first-in-class off-the-shelf therapeutic cancer vaccine candidate in development for the treatment of HPV16-positive cancers.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.56 NOK | -3.00% | +0.41% | -31.96% |
05-14 | Transcript : Nykode Therapeutics AS, Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Nykode Therapeutics AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.96% | 468M | |
+8.38% | 115B | |
+10.13% | 105B | |
-11.69% | 22.71B | |
+2.21% | 21.83B | |
-10.88% | 18.18B | |
-41.90% | 16.52B | |
-16.00% | 16.01B | |
+2.28% | 14.14B | |
+20.54% | 10.71B |
- Stock Market
- Equities
- VACC Stock
- News Nykode Therapeutics
- Nykode Therapeutics Announces Collaboration with The GOG Foundation, Inc. to Conduct the VB-C-04 Trial in Advanced Cervical Cancer